CAN106 is a long-acting, recombinant human monoclonal antibody that specifically binds to and neutralizes C5 in the complement system. C5 is a validated mechanism of action in numerous hematology, nephrology, and neurology diseases, with development potential for the treatment of multiple complement-mediated disorders, including paroxysmal nocturnal haemoglobinuria (PNH). CANbridge is conducting a Phase I PNH study of CAN106 in Singapore, with successive trials planned in China and globally.

CANbridge holds global rights to develop and commercialize CAN106, which it is developing in conjunction with WuXi Biologics (2269.HK), a global company with leading open access biologics technology platforms, as part of a strategic partnership for the development of rare disease therapeutics. CAN106 carries high franchise value and will be competing with other C5 inhibitors and complement dysregulation therapeutics in the global arena.


Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal nocturnal hemoglobinuria (PNH) belongs to a group of fatal and rare disorders that occur when the complement system, a part of the immune system, is dysregulated. In PNH, this results in severe anemia, thromboembolism, gastrointestinal pain and dysfunction, fatigue, pulmonary hypertension, renal impairment, and eventually, death. Treatment options are limited to allogenic bone marrow transplant and the anti-C5 monoclonal antibodies, eculizumab and ravulizumab-cwvz. PNH is an acquired condition that can occur at any age regardless of gender and race, but it most commonly presents in adults in their 30s to 40s and then continues for the life of the patient1. The incidence of PNH in Western countries is estimated to be 1-2 per million per year2. In Asia, the rate is approximately 10 per million per year2.



  1. De Castro C, et al. 2018
  2. China Rare Diseases Diagnosis and Treatment Guide (2019). General Office, National Health Commission. 2019 Edition, 547-554